Status:

COMPLETED

A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Lead Sponsor:

Avalo Therapeutics, Inc.

Conditions:

Non-Eosinophilic Asthma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The primary objective of this study is to evaluate the efficacy of AVTX-002 compared with placebo in patients with poorly controlled non-eosinophilic asthma (NEA).

Eligibility Criteria

Inclusion

  • Documented non-eosinophilic asthma diagnosis (\<300 eosinophils/μL).
  • Symptoms consistent with a diagnosis of asthma that is poorly controlled as determined by an ACQ score ≥ 1.5.
  • Poorly controlled asthma despite the use of a Long-Acting Beta-Agonists and Inhaled Corticosteroid for at least 3 consecutive months immediately prior to screening.
  • Subjects must have had at least one asthma exacerbation in the last 24 months.

Exclusion

  • Pulmonary disease other than asthma.
  • Currently on biologic therapy. Previous biologic therapy is permitted with adequate washout (12 weeks or 5 half-lives, whichever is longer).
  • Use of systemic immunosuppressants within the last 6 months.
  • Use of systemic corticosteroids within 6 weeks prior to Screening or use of antibiotics within 4 weeks prior to Screening.
  • Subject has alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) \>5 upper limit of normal (ULN) and/or serum creatinine concentration \>1.5 mg/dL.
  • Subject has hemoglobin ≤10 g/dL, neutrophils ≤1,500/μl, and/or platelets ≤75,000/μl.

Key Trial Info

Start Date :

February 24 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 11 2023

Estimated Enrollment :

91 Patients enrolled

Trial Details

Trial ID

NCT05288504

Start Date

February 24 2022

End Date

May 11 2023

Last Update

September 5 2024

Active Locations (24)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (24 locations)

1

Tucson Neuroscience Research - M3, Wake Research

Tucson, Arizona, United States, 85710

2

Center For Clinical Trials of Sacramento

Sacramento, California, United States, 95823

3

Allergy and Asthma Medical Group of the Bay Area

Walnut Creek, California, United States, 94598

4

Center For Clinical Trials of San Gabriel

West Covina, California, United States, 91790-3402

A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma. | DecenTrialz